The Flanders formula: inside a leading European biopharma hub

Never has the importance of Flanders’ biopharmaceutical output to the international community been more obvious than it was during the COVID-19 crisis.

At the height of the pandemic, from January to June 2021, some 90% of the vaccines imported to the UK came from the Belgian region.

But in fact, Flanders has long been one of Europe’s leading biopharma hubs, with numerous major research and manufacturing sites. Figures show that its pharma sector has annual revenue in excess of 53 billion euros ($57 billion) and a workforce of 65,000, creating a 23.6 billion euros trade surplus.